With 1 or more claims of siponimod or MS-related FDA-approved DMT during the index calendar year. The date of first claim was the index date.

With 1 or more MS diagnosis for 12 months prior to the index date \[inclusive\].

Were continuously enrolled in pharmacy and medical benefits for 12 months prior to the index date \[inclusive\].

Include patients who were 18 years or older on the index date.

Include patients continuously enrolled in pharmacy and medical benefits from the index date \[inclusive\] to 6 months/12 months post-index date.

Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies